Skip to Content

Biotricity Inc BTCY

Morningstar Rating

Biotricity's Path Towards Breakeven Accelerated by Latest Diagnostic Product, Biotres Pro, Garnering Rapid Interest from Existing and New Customers

Accesswire Apr 26, 2024 11:00am
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics

Accesswire Apr 18, 2024 11:00am
Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital Network

Accesswire Apr 16, 2024 11:00am
Biotricity Announces a Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities

Accesswire Apr 2, 2024 11:15am
LOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire Mar 28, 2024 2:00pm
Biotricity Accelerates Market Access by Partnering with Third Major Group Purchasing Organization, Expanding Market Reach to 90% of U.S. Hospitals

Accesswire Mar 28, 2024 12:15pm
Biotricity Partners with Health Aid Africa to Provide Complementary Heart Health Screenings at Allegiant Stadium Concert

Accesswire Mar 21, 2024 1:20pm
Biotricity Unveils that Improved Margins Resulted from Latest Advancements to its Proprietary Cardiac AI Cloud Platform and Announces Plans for Continued Expansion of its Cardiac AI Cloud

Accesswire Mar 12, 2024 12:45pm
Biotricity Partners with a Second Top Group Purchasing Organization - Positions Company for Expanded Market Access to 1 out of every 2 Hospitals in America

Accesswire Mar 5, 2024 1:15pm
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire Mar 1, 2024 2:00pm
Biotricity Receives Health Canada Clearance for Biotres

Accesswire Feb 29, 2024 1:15pm
Biotricity Strengthens its Foundation for Growth, Achieves Lower Cost of Sales, Expanding Margins of 73% and Increased Device Sales, for Third Quarter of Fiscal Year 2024

Accesswire Feb 21, 2024 1:15pm
Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st

Accesswire Feb 19, 2024 1:00pm
Biotricity Advances Towards Breakeven Milestone - Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024

Accesswire Feb 14, 2024 1:00pm

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.